Greenwich Lifesciences, Inc. (GLSI)
NASDAQ:GLSI
Total Valuation
Greenwich LifeSciences has a market cap or net worth of $343.18M. The enterprise value is $341.62M.
Market Cap$343.18M
Enterprise Value$341.62M
Share Statistics
Greenwich LifeSciences has 14,678,208 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,678,208
Owned by Insiders38.18%
Owned by Institutions0.16%
Financial Efficiency
Greenwich LifeSciences’s return on equity (ROE) is -10.81 and return on invested capital (ROIC) is 154.80%.
Return on Equity (ROE)-10.81
Return on Assets (ROA)2.87
Return on Invested Capital (ROIC)154.80%
Return on Capital Employed (ROCE)1.55
Revenue Per Employee0.00
Profits Per Employee-4.84M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Greenwich LifeSciences is ―. Greenwich LifeSciences’s PEG ratio is -0.81.
PE Ratio―
PS Ratio0.00
PB Ratio158.83
Price to Fair Value158.83
Price to FCF-28.69
Price to Operating Cash Flow-26.64
PEG Ratio-0.81
Income Statement
In the last 12 months, Greenwich LifeSciences had revenue of 0.00 and earned -19.36M in profits. Earnings per share was -1.43.
Revenue0.00
Gross Profit-1.78K
Operating Income-19.45M
Pretax Income-19.36M
Net Income-19.36M
EBITDA-19.36M
Earnings Per Share (EPS)-1.43
Cash Flow
In the last 12 months, operating cash flow was -12.78M and capital expenditures 0.00, giving a free cash flow of -12.78M billion.
Operating Cash Flow-12.78M
Free Cash Flow-12.78M
Free Cash Flow per Share-0.87
Dividends & Yields
Greenwich LifeSciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.63
52-Week Price Change166.89%
50-Day Moving Average24.82
200-Day Moving Average19.21
Relative Strength Index (RSI)45.66
Average Volume (3m)140.51K
Important Dates
Greenwich LifeSciences upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Greenwich LifeSciences as a current ratio of -1.16, with Debt / Equity ratio of 0.00%
Current Ratio-1.16
Quick Ratio-1.16
Debt to Market Cap0.00
Net Debt to EBITDA-0.35
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Greenwich LifeSciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Greenwich LifeSciences EV to EBITDA ratio is -15.04, with an EV/FCF ratio of -29.37.
EV to Sales0.00
EV to EBITDA-15.04
EV to Free Cash Flow-29.37
EV to Operating Cash Flow-29.37
Balance Sheet
Greenwich LifeSciences has $10.51M in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.51M billion.
Cash & Marketable Securities$10.51M
Total Debt$0.00
Net Cash$10.51M
Net Cash Per Share$0.72
Tangible Book Value Per Share-$0.65
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Greenwich LifeSciences is $47.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$47.50
Price Target Upside411.85% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-22.49%